A key advantage of the drug is its oral route of administration, offering patients a more convenient alternative to ...

BeOne Medicines AG (NASDAQ:ONC) saw its stock rise 2.5% in pre-market trading after the European Medicines Agency (EMA) issued a favorable opinion on its cancer drug TEVIMBRA for early-stage lung ...

The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.

(Reuters) -Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer ...

Sarepta Therapeutics failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as ...

The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the ...

Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...

The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.

Eli Lilly and Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group ...

European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.

Despite a new setback for Elevidys in Europe, Roche—which markets Sarepta’s gene therapy outside the U.S.—remains committed ...